1 tracked superinvestor hold BIOXCEL THERAPEUTICS INC (BTAI), worth $970K combined, led by Howard Marks. Smart money is accumulating BTAI as of the latest 13F filings.
Current price
$0.84
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$970K
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
+1
1 buying · 0 selling
Smart money is net accumulating BTAI: 1 funds added or opened versus 0 trimming.
BIOXCEL THERAPEUTICS INC (BTAI) appears mainly in diversified and quant books here (1 funds, $970K combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to Howard Marks at 0% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
No tracked fund opened a new position this quarter; 1 added and 0 trimmed, a net add.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Added | 0% | $970K |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own BTAI?
1 tracked funds hold BIOXCEL THERAPEUTICS INC (BTAI), the largest being Howard Marks (Oaktree Capital Management) at 0% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling BTAI?
In the most recent 13F quarter, 1 tracked fund added or opened BTAI and 0 trimmed it.
How much BTAI do tracked funds hold?
Combined disclosed long exposure to BTAI across tracked superinvestors is $970K as of the Mar 2026 filings.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Mar 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.